Research areas
Stephen Gillespie has worked in Kenya researching the relationship between malaria and lower respiratory tract infection and the prevalence of parasitic infection in children in Kilifi, Kenya. He has investigated a cholera epidemic and vaccine failures in Guerrero, Mexico. He has been working in collaboration with colleagues at Kilimanjaro Christian Medical Centre since 1988 where he has, variously, studied respiratory and parasite diagnostics and novel antimalarials, anti-helminthics and anti tuberculosis agents. His main research activity is in the area of tuberculosis drug development.
For the last twenty five years Stephen Gillespie has been involved in various aspects of tuberculosis diagnosis and drug development. This has included the evaluation of new candidate antituberculosis agents in vitro. This work has expanded into studies of the molecular mechanisms of resistance and the development of model systems to measure the fitness deficits found in resistant strains. He has been involved in the development of fluoroquinolones for tuberculosis having performed early bacterial activity studies and clinical trials of ciprofloxacin. More recently he has led the group working on the clinical development of moxifloxacin in collaboration with the Global Alliance for TB Drug Development as Chief Investigator of the REMox TB study. He later went on to be the coordinating investigator for the TB Alliance STAND trial (Shortening Treatment by Advancing New Drugs) and SimpliciTB trial. He is also one of the Chief Investigators of the PanACEA consortium that links European and African research groups in enhancing anti-tuberculosis therapy.
He has an extensive record of developing novel microbiological diagnostics. Most recently, he has developed SLIC (Scattered Light Integrating Collector), which performs phenotypic antibiotic susceptibility testing in less than 30 minutes. This innovation won a Longitude Prize Discovery Award and was the Scottish Life Science Alliance Innovation of the Year 2017. In addition he has developed the Molecular Bacterial Load Assay, an innovative way of detecting, quantifying and determining the viability of bacteria in a single test that allows both diagnosis and the monitoring of treatment response. Both of these innovations are being developed for clinical implementation.
He has published a number of textbooks in the area of clinicical microbiology and infectious diseases. These include Medical Microbiology and Infection at a Glance now going into its 5th Edition and translated into seven languages, Infection Microbiology and Management now going into its fourth edition also translated into three languages and Medical Microbiology Illustrated. He has edited Principles and Practice of Clinical Parasitology, Principles and Practice of Clinical Bacteriology (two editions) amd Antibiotic Resistance Protocols (Three editions) Management of Drug Resistant Infections and Medical Parasitology.
Selected publications
-
Open access
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
Koele, S. E., Stoycheva, K., Mtweve, C., Manyama, C., Mpagama, S., Mhimbira, F., Wallis, R., Ntinginya, N. E., Liyoyo, A., Huglin, B., Minja, L. T., Wagnerberger, L., Zumba, T., Noreña, I., Peter, D. D., Beattie, T., Makkan, H., Sloan, D. J., Te Brake, L. & Aarnoutse, R. E. & 9 others, , Aug 2025, In: Journal of Antimicrobial Chemotherapy. 80, 8, p. 2305-2313 9 p.Research output: Contribution to journal › Article › peer-review
-
Open access
Data transparency and reproducibility in health research: bridging the gap for early-career researchers
Bhakta, S., Xie, J., Pea, F. & Gillespie, S. H., 29 Apr 2025, In: Frontiers in Antibiotics. 4, p. 1-6 6 p., 1562002.Research output: Contribution to journal › Article › peer-review
-
Open access
Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials
DiNardo, A. R., Sabiiti, W., Gillespie, S. H., Georghiou, S. B., Heinrich, N., Hittel, N., Taghlabi, S., Carrero Longlax, D., Kohli, M., Panzner, U., Musia, C., Lange, C., Vasiliu, A., Arts, R. J. W., Mandalakas, A. M., Ruhwald, M., Stuyver, L. J. & Van Crevel, R., 22 May 2025, In: Frontiers in Antibiotics. 4, p. 1-11 11 p., 1570989.Research output: Contribution to journal › Review article › peer-review
-
Open access
Integrated population clustering and genomic epidemiology with PopPIPE
McHugh, M. P., Horsfield, S. T., von Wachsmann, J., Toussaint, J., Pettigrew, K. A., Czarniak, E., Evans, T. J., Leanord, A., Tysall, L., Gillespie, S. H., Templeton, K. E., Holden, M. T. G., Croucher, N. J. & Lees, J. A., 28 Apr 2025, In: Microbial Genomics. 11, 4, p. 1-9 9 p., 001404.Research output: Contribution to journal › Article › peer-review
-
Open access
Investigating the time to blood culture positivity: why does it take so long?
Falconer, K., Hammond, R., Parcell, B. & Gillespie, S. H., 6 Jan 2025, In: Journal of Medical Microbiology. 74, 1, 10 p.Research output: Contribution to journal › Article
-
Open access
Modelling interventions to combat antibacterial resistance in East Africa using causal Bayesian networks
Ke, X., Smith, V. A., Mshana, S. E., Asiimwe, B., Neema, S., Kiiru, J., Mushi, M. F., Mmbaga, B. T., Mwanga, J. R., Kibiki, G., Stelling, J., Gillespie, S. H., Green, D. L., Benvari, S., Sabiiti, W., Kesby, M., Lynch, A. G., Sandeman, A., Sloan, D. J. & Holden, M. T. & 2 others, , 4 Feb 2025, Research Square.Research output: Working paper › Preprint
-
Open access
Patterns of antibiotic resistance in urinary tract infections before and during the COVID-19 pandemic in Uganda and Tanzania
Silago, V., Keenan, K., Mushi, M. F., Kansiime, C., Asiimwe, B., Sunday, B., Bazira, J., Sandeman, A., Sabiiti, W., Seni, J., Holden, M. T. G., Mshana, S. E. & behalf of the HATUA and CARE Consortia, Apr 2025, In: JAC-Antimicrobial Resistance. 7, 2, p. 1-4 4 p., dlaf038.Research output: Contribution to journal › Article › peer-review
-
Open access
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
Heinrich, N., de Jager, V., Dreisbach, J., Gross-Demel, P., Schultz, S., Gerbach, S., Kloss, F., Dawson, R., Narunsky, K., Matt, L., Wildner, L., McHugh, T. D., Fuhr, U., Aldana, B. H., Mouhdad, C., Brake, L. T., Boeree, M. J., Aarnoutse, R. E., Svensson, E. M. & Gong, X. & 4 others, , 7 Jan 2025, (E-pub ahead of print) In: The Lancet Microbe. Online first, 12 p., 100952.Research output: Contribution to journal › Article › peer-review
-
Tuberculosis molecular bacterial load assay in the management of tuberculosis
Gillespie, S. H. & Sabiiti, W., Apr 2025, In: Current Opinion in Infectious Diseases. 38, 2, p. 176-181Research output: Contribution to journal › Article › peer-review
-
Open access
Accuracy of the tuberculosis molecular bacterial load assay to diagnose and monitor response to anti-tuberculosis therapy: a longitudinal comparative study with standard-of-care smear microscopy, Xpert MTB/RIF Ultra, and culture in Uganda
Musisi, E., Wamutu, S., Ssengooba, W., Kasiinga, S., Sessolo, A., Sanyu, I., Kaswabuli, S., Zawedde, J., Byanyima, P., Kia, P., Muwambi, W., Toskin, D. T., Kigozi, E., Walbaum, N., Dombay, E., Legrady, M. B., Ssemambo, K.D.-M., Joloba, M., Kuchaka, D. & Worodria, W. & 3 others, , Apr 2024, In: The Lancet Microbe. 5, 4, p. e345-e354Research output: Contribution to journal › Article › peer-review